Filtered By:
Condition: Heart Attack
Drug: Insulin

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 348 results found since Jan 2013.

Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
AbstractOwing to the worldwide increase in life expectancy, the high incidence of diabetes in older individuals and the improved survival of people with diabetes, about one-third of all individuals with diabetes are now older than 65  years. Evidence is accumulating that type 2 diabetes is associated with cognitive impairment, dementia and frailty. Older people with diabetes have significantly more comorbidities, such as myocardial infarction, stroke, peripheral arterial disease and renal impairment, compared with those without diabetes. However, as a consequence of the increased use of multifactorial risk factor interven...
Source: Diabetologia - June 4, 2018 Category: Endocrinology Source Type: research

Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints.
CONCLUSION: The combination of metformin with SGLT2i, GLP-1 RA, and a potent statin, in high CVD risk patients with DM, is expected to substantially reduce CVD mortality and morbidity, improving the quality of life of patients with DM at the same time. Prospective studies are needed to confirm this finding. PMID: 29865997 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 3, 2018 Category: Drugs & Pharmacology Authors: Doumas M, Imprialos Κ, Stavropoulos K, Reklou A, Sachinidis A, Athyros VG Tags: Curr Pharm Des Source Type: research

Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes.
CONCLUSIONS: Semaglutide is an appealing option for the treatment of T2D as a once-weekly GLP-1 RA with established glycemic, CV, and weight benefits. PMID: 29932006 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - June 1, 2018 Category: Drugs & Pharmacology Authors: Tuchscherer RM, Thompson AM, Trujillo JM Tags: Ann Pharmacother Source Type: research

Con: continuous positive airway pressure and cardiovascular prevention
For the last two decades, evidence has been mounting that obstructive sleep apnoea (OSA) may be a cause of cardiovascular disease (CVD). OSA causes repeated acute falls in nocturnal arterial blood oxygen saturation, and rises in blood pressure and heart rate. These physiological changes, combined with the acute mechanical stress placed on the heart from the often very large negative pleural pressure swings during obstructed breathing, were postulated to provide the substrate necessary to induce acute events such as myocardial infarction, arrhythmias, acute heart failure, stroke and sudden cardiovascular death. Observationa...
Source: European Respiratory Journal - May 10, 2018 Category: Respiratory Medicine Authors: McEvoy, R. D., Kohler, M. Tags: Editorials Source Type: research

Randomized placebo controlled trial evaluating the safety and efficacy of single low-dose intracoronary insulin-like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI)
Conclusions In this pilot trial, low-dose IGF1, given after optimal mechanical reperfusion in STEMI, is safe but does not improve LVEF. However, there is a signal for a dose-dependent benefit on post-MI remodeling that may warrant further study.
Source: American Heart Journal - May 8, 2018 Category: Cardiology Source Type: research

Finding Good Candidates for Risk-Sharing Arrangements
Continued from Part I that discusses the tools device manufacturers can use to manage risk How to find good candidates? Not all devices are created equal. But how can device manufacturers identify the low-hanging fruit for a risk-sharing arrangement? Needless to say, the more characteristics a product has that are associated with successful risk-sharing arrangements, the more such an arrangement is likely to succeed. To illustrate, in Exhibit 1, we chart a select number of risk-sharing arrangements established since 2015 along two key dimensions: product effectiveness and time needed to observe expected outcomes. The findi...
Source: MDDI - April 3, 2018 Category: Medical Devices Authors: Harry Liu and Christine Chen Tags: Contract Manufacturing Design Source Type: news

Randomized placebo controlled trial evaluating the safety and efficacy of single low dose intracoronary insulin like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI)
Conclusion In this pilot trial, low dose IGF1, given after optimal mechanical reperfusion in STEMI, is safe but does not improve LVEF. However, there is a signal for a dose dependent benefit on post MI remodeling that may warrant further study.
Source: American Heart Journal - April 3, 2018 Category: Cardiology Source Type: research

Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women Original Articles
Conclusions: Circulating plasma BCAAs were positively associated with incident CVD in women. Impaired BCAA metabolism may capture the long-term risk of the common cause underlying T2D and CVD.
Source: Circulation: Cardiovascular Genetics - March 23, 2018 Category: Cardiology Authors: Tobias, D. K., Lawler, P. R., Harada, P. H., Demler, O. V., Ridker, P. M., Manson, J. E., Cheng, S., Mora, S. Tags: Biomarkers, Cardiovascular Disease, Diabetes, Type 2, Epidemiology, Women Original Articles Source Type: research

Glucagon treatment in type 1 diabetes -with focus on restoring plasma glucose during mild hypoglycemia 
.
Glucagon treatment in type 1 diabetes -with focus on restoring plasma glucose during mild hypoglycemia
. Dan Med J. 2018 Feb;65(2): Authors: Ranjan A Abstract Type 1 diabetes is a chronic disease caused by an autoimmune destruction of the insulin-producing cells in the pancreas, leading to a condition with insulin deficiency and elevated blood glucose levels. Individuals with type 1 diabetes are therefore recommended to frequently inject insulin subcutaneously to keep near-normal blood glucose levels, preventing the progression and onset of diabetes-related complications, i.e. kidney failure, blindne...
Source: Danish Medical Journal - February 3, 2018 Category: General Medicine Tags: Dan Med J Source Type: research

Plasma proprotein ‐convertase‐subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes
ConclusionsWe found that PCSK9 was inconsistently associated with CV events in populations with type 2 diabetes. The association may depend on the level of CV risk and the background treatment.
Source: Diabetes, Obesity and Metabolism - January 14, 2018 Category: Endocrinology Authors: Petra El Khoury, Ronan Roussel, Frederic Fumeron, Yara Abou ‐Khalil, Gilberto Velho, Kamel Mohammedi, Marie‐Paule Jacob, Philippe Gabriel Steg, Louis Potier, Youmna Ghaleb, Sandy Elbitar, Stephanie Ragot, Francesco Andreata, Giusepinna Caligiuri, Samy Tags: ORIGINAL ARTICLE Source Type: research

The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.
CONCLUSIONS: Incretin-based therapies show similar cardiovascular risk in comparison with metformin, insulin, thiazolidinediones, alpha-glucosidase inhibitor and sodium-glucose co-transporter 2. GLP-1RA could decrease the risk compared with sulfonylurea or placebo, while DPP-4I appears to have neutral effect on cardiovascular risk. PMID: 29320889 [PubMed - as supplied by publisher]
Source: Expert Opinion on Drug Safety - January 13, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Glycemic variability, but not HbA1c, is associated with high SYNTAX scores at the acute phase of myocardial infarction (AMI) in diabetic patients treated with insulin infusion
Conclusion GV was mainly associated with diabetes-related factors, and was independently associated with a high SYNTAX score. Our findings suggest that assessment of blood GV could contribute to the identification of high-risk diabetics and become a therapeutic target in primary and secondary prevention.
Source: Archives of Cardiovascular Diseases Supplements - January 5, 2018 Category: Cardiology Source Type: research

DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
Conclusions/interpretationThe results from these analyses demonstrate an association between severe hypoglycaemia and all-cause mortality. Furthermore, they indicate that patients who experienced severe hypoglycaemia were particularly at greater risk of death in the short term after the hypoglycaemic episode. These findings indicate that severe hypoglycaemia is associated with higher subsequent mortality; however, they cannot answer the question as to whether severe hypoglycaemia serves as a risk marker for adverse outcomes or whether there is a direct causal effect.Trial registrationClinicalTrials.gov NCT01959529
Source: Diabetologia - December 6, 2017 Category: Endocrinology Source Type: research

Plasma PCSK9 and Cardiovascular Events in Type 2 Diabetes
ConclusionsPCSK9 is inconsistently associated with CV events in populations with T2DM. The association may depend on the level of CV risk and the background treatment
Source: Diabetes, Obesity and Metabolism - December 5, 2017 Category: Endocrinology Authors: Petra El Khoury, Ronan Roussel, Frederic Fumeron, Yara Abou ‐Khalil, Gilberto Velho, Kamel Mohammedi, Marie‐Paule Jacob, P. Gabriel Steg, Louis Potier, Youmna Ghaleb, S El Bitar, S Ragot, Francesco Andreata, Giusepinna Caligiuri, Samy Hadjadj, Catheri Tags: ORIGINAL ARTICLE Source Type: research

Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack.
CONCLUSIONS: Peroxisome proliferator-activated receptor gamma agonists probably reduce recurrent stroke and total events of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, and may improve insulin sensitivity and the stabilisation of carotid plaques. Their effects on adverse events are uncertain. Our conclusions should be interpreted with caution considering the small number and the quality of the included studies. Further well-designed, double-blind RCTs with large samples are required to assess the efficacy and safety of PPAR-γ agonists in the secondary prevention of stroke and related vascular...
Source: Cochrane Database of Systematic Reviews - December 2, 2017 Category: General Medicine Authors: Liu J, Wang LN Tags: Cochrane Database Syst Rev Source Type: research